Leo Pharma's eczema drug for adolescents meets phase III trial targets

The drug Adtralza, which is developed by Leo Pharma, has reached both its primary and secondary endpoints after a 16-week phase III trial testing the eczema treatment in patients with moderate-to-severe atopic dermatitis.

BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

Published: 25.10.21 at 12:51

At the 2021 Fall Clinical Dermatology Conference, held virtually and from Las Vegas, pharmaceutical company Leo Pharma presented data from a new trial of its antibody treatment tralokinumab, sold under the brand name Adtralza, which is approved in the EU, the UK and Canada as a treatment for adults with moderate-to-severe atopic dermatitis.

The new results come from the phase III trial Ecztra 6, which has investigated the treatment in the younger segment of patients aged 12 to 17. The participants have received Adtralza over 16 weeks in one of two dosages, or a placebo substance.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.